Related Experiment Video

Updated: Aug 9, 2026

Autonomous and Rechargeable Microneurostimulator Endoscopically Implantable into the Submucosa
08:17

Autonomous and Rechargeable Microneurostimulator Endoscopically Implantable into the Submucosa

Published on: September 27, 2018

Implantable gastric stimulation for the treatment of severe obesity

Scott A Shikora1

  • 1Tufts University School of Medicine, Tufts-New England Medical Center, Boston, MA 02111, USA. sshikora@tufts-nemc.org

Obesity Surgery
|May 8, 2004
PubMed

More Related Videos

Sleeve Gastrectomy in Mice using Surgical Clips05:16

Sleeve Gastrectomy in Mice using Surgical Clips

Published on: November 14, 2020

Implantation Surgery for Abdominal Vagus Nerve Stimulation and Recording Studies in Awake Rats07:17

Implantation Surgery for Abdominal Vagus Nerve Stimulation and Recording Studies in Awake Rats

Published on: January 19, 2024

Related Concept Videos

Peptic Ulcer Disease V: Surgical Management and Nursing Care01:25

Peptic Ulcer Disease V: Surgical Management and Nursing Care

Surgical management and nursing care are crucial in treating Peptic Ulcer Disease (PUD). Here is an organized and enhanced overview of the surgical interventions and the associated nursing care for PUD:
Surgical Interventions for Peptic Ulcer Disease
Enteral Nutrition II: Nasointestinal and Gastrostomy Feeding01:15

Enteral Nutrition II: Nasointestinal and Gastrostomy Feeding

Enteral nutrition encompasses various methods of delivering nutrition directly to the gastrointestinal (GI) tract, bypassing traditional oral intake. It is particularly beneficial for patients who cannot eat by mouth but have a functioning digestive system. Key methods include nasointestinal feeding, gastrostomy, and jejunostomy, each suited to different clinical scenarios based on the patient's needs and condition.
Nasointestinal Feeding
Nasointestinal feeding involves placing a tube through...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...